Molecules of the MillenniumJournal of Pharmacology and PharmacotherapeuticsVol. 5 | Issue 2 | 2014 | pp. 175–178Open access
Lorcaserin: A novel antiobesity drug
- 1*,
- 1,
- 1,
- 1,
- 1
- 1 Department of Pharmacology, Armed Forces Medical College, Pune, Maharashtra, India.
Published in Journal of Pharmacology and Pharmacotherapeutics
Correspondence: Dick B. S. Brashier
Department of Pharmacology, Armed Forces Medical College, Pune, Maharashtra, India.
Email: drdickbrashier@gmail.com
Copyright: © 2014 Manuscript Technomedia LLP. This is an open access article.
- Published:
- Jan 1, 2014
- Received:
- Mar 24, 2013
- Accepted:
- Feb 27, 2014
How to cite
Brashier, D. B. S., Sharma, A. K., Dahiya, N., Singh, S. K., & Khadka, A. (2014). Lorcaserin: A novel antiobesity drug. Journal of Pharmacology and Pharmacotherapeutics, 5(2), 175–178. https://doi.org/10.4103/0976-500X.130158
Abstract
Obesity is a major co-morbidity with hypertension and diabetes mellitus. There are few drugs for treatment of obesity like orlistat and recentlty approved drug lorcaserin. Lorcaserin has serotonergic properties and acts as an anorectic. It may cause serious side effects, including serotonin syndrome, particularly when taken with certain medicines that increase serotonin levels or activate serotonin receptors. Although, mainstay and first line of approach of treatment will always remain in having low calorie diet and increase in physical activity. Lorcaserin has come as a new hope to achieve success in treating obese patients but still a long road with further extensive research to be undertaken in the treatment of obesity.
Keywords
Subject
Article metadata
| Title | Lorcaserin: A novel antiobesity drug |
|---|---|
| Authors | Dick B. S. Brashier; A. K. Sharma; Navdeep Dahiya; S. K. Singh; Anjan Khadka |
| Affiliations | Department of Pharmacology, Armed Forces Medical College, Pune, Maharashtra, India. |
| Corresponding author | drdickbrashier@gmail.com |
| Journal | Journal of Pharmacology and Pharmacotherapeutics |
| Volume / Issue | Vol. 5, Issue 2 (2014) |
Also in this issue
- Why patients in pain cannot get “God’s own medicine?”pp. 81–2
- Switch over from intravenous to oral therapy: A concise overviewpp. 83–87
- Off‑label use of medicine: Perspective of physicians, patients, pharmaceutical companies and regulatory authoritiespp. 88–92
- Folic acid supplementation on homocysteine levels in children taking antiepileptic drugs: A randomized controlled trialpp. 93–94
- Identification of risk factors for carbamazepine‑induced serious mucocutaneous adverse reactions: A case‑control study using data from spontaneous adverse drug reaction reportspp. 100–138
Readers Also Viewed
Development and Validation of UV/visible Spectrophotometric Method for Estimation of Piroxicam from Bulk and Formulation
Sandip Mohan Honmane, Kunal Rajaram Yadav, Yuvraj Dilip Dange
Apr 23, 2025
Effects of Artificial Intelligence on Academic Performance of Library and Information Science University Students: A Meta-Analysis (2023-2025)
Kayode Sunday John Dada
Aug 6, 2026
Bridging Innovation and Impact: A Multidisciplinary Approach to Contemporary Research Challenges
Mueen Ahmed KK
Aug 11, 2026